Retinal Artery and Vein Occlusion Risks after Coronavirus Disease 2019 or Coronavirus Disease 2019 Vaccination.

Autor:	Park HS; Department of Ophthalmology, College of Medicine, Soonchunhyang University, Cheonan, South Korea; Department of Ophthalmology, Soonchunhyang University Hospital Bucheon, Bucheon, South Korea., Lee NK; Department of Computer Science and Engineering, Sungkyunkwan University, Suwon, South Korea., Lee CS; The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea., Byeon SH; The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea., Kim SS; The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea., Lee SW; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, South Korea. Electronic address: lsw2920@gmail.com., Kim YJ; The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: kyjcolor@naver.com.
Jazyk:	angličtina
Zdroj:	Ophthalmology [Ophthalmology] 2024 Mar; Vol. 131 (3), pp. 322-332. Date of Electronic Publication: 2023 Sep 20.
DOI:	10.1016/j.ophtha.2023.09.019
Abstrakt:	Purpose: To evaluate the incidence of new retinal artery occlusion (RAO) and retinal vein occlusion (RVO) after the diagnosis of coronavirus disease 2019 (COVID-19) or vaccination against COVID-19 and compare the incidences with the population with neither. Design: Nationwide population-based cohort study. Participants: From a nationwide population-based cohort, 8 418 590 patients were categorized into control (group 1), COVID-19 infection (group 2), and COVID-19 vaccination (group 3) groups. Methods: The cumulative incidence of RAO and RVO was calculated in groups 1, 2, and 3 using the Kaplan-Meier method. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) based on the Poisson distribution for RAO and RVO according to each group and subgroup using Cox proportional hazards models, with group 1 as the reference. We conducted univariable and multivariable analyses for the risk factors of RAO and RVO according to each subgroup. Main Outcome Measures: Cumulative incidence and risks of incidence of RAO and RVO from the index date to day 60. Results: In multivariable analysis, no significant increase in RAO and RVO risks after COVID-19 or COVID-19 vaccination were observed in either men or women. These results were observed consistently across various conditions in sensitivity analyses. In subgroup analysis, individuals who were vaccinated before infection showed no significant increase in RAO or RVO risks in both sexes compared with the control group. In the subgroup analysis of vaccinated patients, the HRs of RAO and RVO for different vaccine types did not show an increase compared with the control group; however, an exception was observed in women who received mRNA-1273 vaccines, who showed a higher RAO HR (4.65; 95% CI, 1.27-17.03; P = 0.021). Conclusions: Within 60 days of COVID-19 diagnosis or vaccination, RAO and RVO occurred rarely. We observed no increase in the HR of RVO and RAO relative to COVID-19 or COVID-19 vaccination except for a possible increase in the RAO HR in women who received mRNA-1273, for which the raw incidence was extremely low. Further investigation is required to validate this result. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. (Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu